Akduman, B., & Crawford, E. (2001, Dec). Terazosin, doxazosin, and prazosin:
Current clinical experience. [Review] [37 refs]. Urology., 58(6 Suppl 1), 49-54.
Batista-Miranda, J., Diez, M., Bertran, P., & Villavicencio, H. (2001).
Quality-of-life assessment in patients with benign prostatic hyperplasia: Effects
of various interventions. [Review] [58 refs]. Pharmacoeconomics., 19(11), 1079-90.
Beduschi, M., Beduschi, R., & Oesterling, J. (1998, Jun). Alpha-blockade
therapy for benign prostatic hyperplasia: From a nonselective to a more selective
alpha1A-adrenergic antagonist. [Review] [50 refs]. Urology., 51(6), 861-72.
Beduschi, R., Beduschi, M., & Oesterling, J. (1998, Mar). Benign prostatic
hyperplasia: Use of drug therapy in primary care. [Review] [25 refs]. Geriatrics.,
53(3), 24-8.
Chapple, C. (1998, Mar). Pharmacotherapy for benign prostatic hyperplasia--the
potential for alpha 1-adrenoceptor subtype-specific blockade. [Review] [109
refs]. British Journal of Urology., 81(Suppl 1), 34-47.
Clifford, G., & Farmer, R. (2000, Jul). Medical therapy for benign prostatic
hyperplasia: A review of the literature. [Review] [136 refs]. European Urology.,
38(1), 2-19.
Ebbs, D. (2001). A comparison of selected antihypertensives and the use of conventional
vs ambulatory blood pressure in the detection and treatment of hypertension.
Cardiology., 96(Suppl 1), 3-9.
Kirby, R. (1998, Sep). Expanding role of alpha adrenoceptor blockade in the
treatment of benign prostatic hyperplasia. [Review] [44 refs]. International
Journal of Clinical Practice., 52(6), 402-7.
Mikhailidis, D., Khan, M., Milionis, H., & Morgan, R. (2000). The treatment
of hypertension in patients with erectile dysfunction. [Review] [30 refs]. Current
Medical Research & Opinion., 16(Suppl 1), s31-6.
Mori, Y., Matsubara, H., Nose, A., Shibasaki, Y., Masaki, H., Kosaki, A., et
al. (2001, Jul). Safety and availability of doxazosin in treating hypertensive
patients with chronic renal failure. Hypertension Research, 24(4), 359-63.
Poulter, N., & Williams, B. (2001, Nov). Doxazosin for the management of
hypertension: Implications of the findings of the ALLHAT trial. American Journal
of Hypertension., 14(11 Pt 1), 1170-2.
Pressel, S., Davis, B., Wright, J., Geraci, T., Kingry, C., Ford, C., et al.
(2001, Feb). Operational aspects of terminating the doxazosin arm of The Antihypertensive
and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Controlled
Clinical Trials., 22(1), 29-41.
Zusman, R. (2000, Jan-Feb.). The role of alpha 1-blockers in combination therapy
for hypertension. [Review] [48 refs]. International Journal of Clinical Practice.,
54(1), 36-40.